Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclidinium/Formoterol vs Formoterol in COPD
NCT00706914Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Jun 2008
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aclidinium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoints: Change From Baseline in Weekly Average Nocturnal Symptom Scores at 4 weeks and Change From Baseline in Weekly Average Daily (24 Hour) Sputum Volume Scores at 4 weeks. Started Jun 2008; status: terminated.
02
Drugs
aclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00706914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00706914.